Literature DB >> 1319161

Characterization of camptothecin-resistant Chinese hamster lung cells.

J Y Chang1, L A Dethlefsen, L R Barley, B S Zhou, Y C Cheng.   

Abstract

Three camptothecin-resistant sublines (V79r, IRS-1r and IRS-2r) of V79 cells and their irradiation-sensitive mutants, IRS-1 and IRS-2, were developed by stepwise, continuous exposure to camptothecin (CPT). The degree of resistance varied among these cells. Based on the biochemical characterizations of these resistant cell lines, the mechanisms which could be responsible for the resistance to CPT were proposed to be: (a) a decrease in the intracellular accumulation of CPT with or without alteration of DNA topoisomerase I, (b) a decrease in the amount of DNA topoisomerase I, or (c) a decrease in the sensitivity of DNA topoisomerase I to CPT. The resistant cells which exhibited down-regulation of DNA topoisomerase I were collaterally sensitive to etoposide (VP-16) and its analogue, 4'-demethy-4 beta-(4"-fluoroanilino)-4-desoxypodophyllotoxin, despite the fact that there were equal amounts of DNA topoisomerase II in the parental and in the resistant cell lines. Alternating the usage of CPT and VP-16 for the treatment of cancer is indicated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1319161     DOI: 10.1016/0006-2952(92)90325-d

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

2.  Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32.

Authors:  P N Adjei; S H Kaufmann; W Y Leung; F Mao; G J Gores
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

3.  Clinical, pharmacokinetic and biological studies of topotecan.

Authors:  P J O'Dwyer; F P LaCreta; N B Haas; T Halbherr; H Frucht; E Goosenberg; K S Yao
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.

Authors:  W J Jansen; T M Hulscher; J van Ark-Otte; G Giaccone; H M Pinedo; E Boven
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

5.  Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

Authors:  V M Herben; W W ten Bokkel Huinink; A C Dubbelman; I A Mandjes; Y Groot; D M van Gortel-van Zomeren; J H Beijnen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.

Authors:  M Sorensen; M Sehested; I J Christensen; J K Larsen; P B Jensen
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

7.  Determinants of CPT-11 and SN-38 activities in human lung cancer cells.

Authors:  J van Ark-Otte; M A Kedde; W J van der Vijgh; A M Dingemans; W J Jansen; H M Pinedo; E Boven; G Giaccone
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

8.  Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.

Authors:  M Sorensen; M Sehested; P B Jensen
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.